Camargo CEO and leadership

Dan Duffy is a Chief Business Dev Ofcr at Biologics Inc and Chief Executive Officer at Camargo Pharmaceutical Services. He has worked as Exec VP/General Manager at Biologics Inc and VP/General Manager at McKesson Specialty Health. Dan works or has worked as CHAIRMAN at North Carolina Institute On Blindness.

Dr. Ruth Stevens has more than 20 years of experience in the development of new drugs and therapeutic agents. She has led more than 100 FDA regulatory meetings in her career and continues to lead numerous meetings. She has authored more than 70 abstracts/publications and is frequently requested as a speaker both nationally and internationally. In addition, Stevens served as an Advisory Committee Member (non-voting) to the FDA’s Blood Products Advisory Committee Meeting in 2013.

Before joining Camargo, Stevens was senior director of clinical affairs at Duramed Pharmaceuticals overseeing Phase I-IV scientific and clinical activities, with an emphasis on women’s health and HRT products. She also served as director of pharmacokinetics and pharmacodynamics at Phoenix International Life Sciences where she was responsible for scientific management of clinical pharmacology Phase I and II studies.

Stevens began her career at the FDA as a pharmacokinetic reviewer and a team leader in the Office of Clinical Pharmacology and Biopharmaceutics in the Center for Drug Evaluation and Research (CDER).

Carter Gaither is a CFO/Head:Corporate Development at Camargo Pharmaceutical Services. He has worked as Managing Director at Union Springs Pharmaceuticals LLC.

Jennie Orr is a Chief Strategy and Business Officer at Camargo Pharmaceutical Services and is based in North Carolina. She has worked as Consultant at Monitor Group. Jennie works or has worked as Executive Director, Vaccines at LIQUIDIA CORP. She studied at Stanford University Graduate School of Business between 2004 and 2006 and DARTMOUTH COLLEGE between 1996 and 1999.

• Thirty (30) years of combined experience in the medical and clinical research industries.

• Strong experience with planning, implementing, leading and evaluating global projects.

• Management skills include leading teams in the development and execution of clinical studies to include resourcing, budgeting, data and study management, statistics, programming, SAE reporting, trend analysis, safety signaling and medical writing.

• Therapeutic areas of experience include Cardiovascular, Anti-Infectives, Hematology, Immunology, Endocrinology, Dermatology, and Gastroenterology in phase I-IV studies.

• International regulatory interactions - worldwide including direct meetings and multiple submissions (NDA, IND, CTA, orphan drug, pre meeting packages)

• Extensive safety monitoring experience.

• Medical experience includes successful medical practice in internal/general medicine, hospital Chief of Staff and Hospice Director.

Reeves McGee is responsible for Camargo’s commercial activities and relationships including sales, business development, and client program management and oversees the development and implementation of commercial strategies for Camargo. He has more than 20 years of leadership experience in various industries, in roles spanning business development, corporate development, and strategic planning. In addition to his experience in the private sector, Reeves started his career serving our country as a supply and logistics officer in the United States Navy on the aircraft carrier USS ENTERPRISE.

Reeves is also an active volunteer leader with The Leukemia & Lymphoma Society (LLS). He currently serves as Chair of the Triangle Board of Trustees for the North Carolina LLS chapter.

Reeves earned a BA in economics from Duke University and an MBA from the University of North Carolina at Chapel Hill.

Dr. Ruth Stevens has more than 20 years of experience in the development of new drugs and therapeutic agents. She has led more than 100 FDA regulatory meetings in her career and continues to lead numerous meetings. She has authored more than 70 abstracts/publications and is frequently requested as a speaker both nationally and internationally. In addition, Stevens served as an Advisory Committee Member (non-voting) to the FDA’s Blood Products Advisory Committee Meeting in 2013.

Before joining Camargo, Stevens was senior director of clinical affairs at Duramed Pharmaceuticals overseeing Phase I-IV scientific and clinical activities, with an emphasis on women’s health and HRT products. She also served as director of pharmacokinetics and pharmacodynamics at Phoenix International Life Sciences where she was responsible for scientific management of clinical pharmacology Phase I and II studies.

Stevens began her career at the FDA as a pharmacokinetic reviewer and a team leader in the Office of Clinical Pharmacology and Biopharmaceutics in the Center for Drug Evaluation and Research (CDER).